Vanguard Advisers Inc
EW icon

Vanguard Advisers Inc’s Edwards Lifesciences EW Stock Holding History

Vanguard Advisers Inc’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$995 Buy
+11
New +$921 ﹤0.01% 611

Other funds holding EW

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Vanguard Advisers Inc's EW Position: Q2 2026 in Review

Vanguard Advisers Inc opened a new position in Edwards Lifesciences (EW) in Q2 2026: 11 shares worth $995. The stake represents ﹤0.01% of the portfolio and ranks #611 among its holdings.

1,299 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Vanguard Advisers Inc held 11 shares of Edwards Lifesciences worth $995 as of Q2 2026.
  • Edwards Lifesciences was a new Vanguard Advisers Inc position in Q2 2026.
  • Edwards Lifesciences made up ﹤0.01% of Vanguard Advisers Inc's portfolio in Q2 2026, its #611 holding.
  • 1,299 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Vanguard Advisers Inc's 13F filing for Q2 2026, filed 13 Aug 2026.